Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NetriCan

Financiado

Cerrado

Characterization of the role of netrin 1 in the regulation of the Epithelial to...

Characterization of the role of netrin 1 in the regulation of the Epithelial to Mesenchymal Transition during tumor progression. Recent data coming from both basic research and clinical trials converge toward the importance of the epithelial/mesenchymal status of a tumor to respond to conventional chemotherapies and immune-checkpoint inhibitors. These obser... ver más

30/11/2022

UNIVERSITE LYON 1...

197K€

Presupuesto del proyecto: 197K€

Líder del proyecto

UNIVERSITE LYON 1 CLAUDE BERNARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-11-30

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITE LYON 1 CLAUDE BER...

196.71K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2014-53128-R PLASTICIDAD Y COMPORTAMIENTO CELULAR EN HOMEOSTASIS EPITELIA... Cerrado

BFU2017-85420-R EPIGENETICA DEL PROCESO DE TRANSICION DE EPITELIO A MESENQUI... 242K€ Cerrado

BFU2015-73494-JIN ANALISIS COMPARATIVO DE LOS ROLES DE SNAIL Y GATA FACTORES E... 194K€ Cerrado

SAF2016-75702-R MECANISMOS REGULADORES DE PLASTICIDAD EN MELANOMA. PAPEL DE... 182K€ Cerrado

SAF2013-48849-C2-1-R TRANSICION EPITELIO-MESENQUIMA Y DESARROLLO TUMORAL: ANALISI... 472K€ Cerrado

MechTransition Regulatory mechanisms controlling a new mechanical Epithelia... 225K€ Cerrado

Duración del proyecto: 32 meses Fecha Inicio: 2020-03-04
Fecha Fin: 2022-11-30

Líder del proyecto

UNIVERSITE LYON 1 CLAUDE BERNARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 197K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Recent data coming from both basic research and clinical trials converge toward the importance of the epithelial/mesenchymal status of a tumor to respond to conventional chemotherapies and immune-checkpoint inhibitors. These observations set the Epithelial-to-Mesenchymal Transition (EMT) program at the centre of cancer biology. Besides its multiple roles in development and during adulthood, EMT is activated during tumor progression not only to allow metastatic dissemination of cancer cells, which is responsible for the vast majority of patients’ death, but also to provide cells with stem-like properties and resistance mechanisms to survive chemotherapy. It is now widely accepted that future therapies will have to target and/or block the EMT process and allow conventional therapies to efficiently kill the differentiated, epithelial cells to treat patients with advanced solid tumors. NetriCan will analyse for the first time the implication of netrin-1 and its dependence receptor UNC5B in the regulation of EMT, either directly or via its cell death-related function. Moreover, the re-epithelialization effect of the anti-netrin-1 monoclonal antibody observed in tumors in vivo and in a preliminary cohort of patients shows that netrin-1/UNC5B may not only be involved in the direct regulation of maintenance of EMT but also serve as a survival mechanism for metastatic tumor cells. To achieve this, Netrican will first analyse how the upregulation of netrin-1 and UNC5B is regulated during EMT. It will then investigate the role of the netrin-1/UNC5B axis in the establishment and maintenance of the EMT program needed for cell dissemination and metastasis. Finally, this project will elucidate the therapeutic potential of the anti-netrin-1 strategy for both triggering primary tumor re-epithelialization and killing mesenchymal tumor cells. In summary, NetriCan will provide innovative findings to develop novel promising therapeutic approach for patients with advanced solid tumors.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores